Dr. Kameron S. Rezzadeh, MD

Dr. Rezzadeh practices at Dignity Health - California Hospital Medical Center in Los Angeles, California, part of CommonSpirit Health.

Dr. Rezzadeh's NPI, 1871955153, was assigned on March 24, 2016. Dr. Rezzadeh graduated from Rutgers Robert Wood Johnson Medical School in 2016. Dr. Rezzadeh's California license number on file is A154343.

Dr. Rezzadeh's primary practice is Dignity Health - California Hospital Medical Center, at 1401 South Grand Avenue, Los Angeles, CA 90015 in Los Angeles County. The practice phone is (213) 748-2411.

Dr. Rezzadeh's primary practice is Dignity Health - California Hospital Medical Center in Los Angeles, California, part of CommonSpirit Health. The medical group on file is California Dermatology Institute. Dmand AI also links Dr. Rezzadeh to 2 more group practices and clinics, 2 medical groups and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rezzadeh practices, 4 sites in all. Vendor and product names are available with a free account.

Plastic surgery is Dr. Rezzadeh's primary specialty in the NPI Registry, under taxonomy code 208200000X. Dr. Rezzadeh is board certified in plastic surgery by the American Board of Plastic Surgery. Dr. Rezzadeh has a license on file in California.

CMS data shows 78 Medicare services from Dr. Rezzadeh across 5 procedure codes in 2024, for 122 Medicare patients. Medicare paid $50,166 for them. Every service was in an office.

CMS counts 122 Medicare patients who saw Dr. Rezzadeh in 2024. The largest group is 75 to 84, with 49 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rezzadeh's median patient age at 63, with 50% women.

In 2024, Dr. Rezzadeh wrote 14 Medicare Part D claims. 100% of them were for generic drugs. They cover 2 drugs, with $199 in total drug cost. In 2019, CMS named 53 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Rezzadeh for performance year 2024, reported as part of a group. Dr. Rezzadeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 12 procedures of melanoma (skin cancer) excision by Dr. Rezzadeh, more than 66% of the clinicians it reports for that procedure.

Dmand AI links 11 papers to Dr. Rezzadeh, published from 2015 to 2021. 2015 was the busiest year, with 5. Dr. Rezzadeh's most frequent co-authors are Lily Daniali, MD, Andrew John Li, MD and Miles J. Pfaff, MD.

CMS Open Payments shows 33 general payments to Dr. Rezzadeh from 16 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 62% of the total. Micromed Inc paid the most, $1,151.

Dr. Rezzadeh graduated from Rutgers Robert Wood Johnson Medical School in 2016.

Dr. Rezzadeh is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.